Welcome to LookChem.com Sign In|Join Free

CAS

  • or

122-09-8

Post Buying Request

122-09-8 Suppliers

Recommended suppliersmore

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

122-09-8 Usage

Originator

Wilpo ,Dorsey, US,1961

Uses

Appetite suppressant (systemic).

Manufacturing Process

Preparation of isobutyrophenone: In a 12 liter, 3-necked flask, 1,280 grams of aluminum chloride was covered with 2,000 cc of dry thiophene-free benzene and a solution of 919 grams of isobutyryl chloride, (BP 92°-94°C) in 1 liter of benzene was added slowly with stirring. After heating for 3 hours at reflux, the solution was cooled and poured over a mixture of 1 liter of concentrated hydrochloric acid and 5 kg of ice. The benzene layer was separated, the aqueous layer extracted with benzene, and the combined benzene solutions were washed, dried and concentrated in vacuo. The residue was distilled rapidly to give 1,051 grams of isobutyrophenone, boiling at 81°-89°C at 1 mm, yield 83.4%.Preparation of 1,3-Diphenyl-2,2-Dimethylpropanone-1: Sodamide was prepared from 12.5 grams of sodium added in small portions to 600 cc of liquid ammonia with 1 gram of hydrous ferric chloride as catalyst. The ammonia was replaced by 200 cc of dry toluene and without delay a solution of 74 grams of isobutyrophenone and 76.5 grams of benzyl bromide in 200 cc of benzene was slowly added with stirring. The reaction mixture was heated on a boiling water bath for 48 hours. Water was then added, the organic layer separated and the product isolated by distillation. The 1,3-diphenyl-2,2 Phentermine dimethylpropanone-1 boiled from 142°-143°C at a pressure of 3 mm, nD201.5652.Preparation of α,α-Dimethyl-β-Phenylpropionamide: Sodamide was prepared from 7.6 grams of sodium in 350 cc of liquid ammonia with 0.9 gram of hydrous ferric chloride. The ammonia was replaced by 250 cc of toluene, the mixture was heated to 60°C and 71.4 grams of 1,3-diphenyl-2,2-dimethyl propanone-1 dissolved in 150 cc of toluene was added. The mixture was stirred and heated on a steam bath for 5 hours. A clear red color appeared in 15 minutes and disappeared after about an hour. After cooling, water was added, the organic layer was washed, dried, and concentrated to give 36.5 grams of α,α-dimethyl-β-phenyl propionamide which crystallized slowly after the addition of an equal volume of petroleum ether. The product melted at 62°C after crystallization from benzene-petroleum ether.Preparation of Di-(β-Phenyl-α,α-Dimethylethyl)Urea: 3.5 grams of α,αdimethyl-β-phenylpropionamide in 420 cc of water was added to a solution of 87.5 grams of potassium hydroxide and 35 grams of bromine in 350 cc of water. After 2 hours at 60°C, the product was obtained on crystallization from ethanol, melting at 184°C.Preparation of ω-Phenyl-tert-Butylamine: 24 grams of the urea derivative obtained as indicated above, were well mixed with 96 grams of calcium hydroxide in a flask immersed in an air bath and provided with a dropping funnel the stem of which reached the bottom of the flask. The mixture was heated to 240°-260°C (inside temperature) for 7 hours during which time 86 cc of water was slowly added. The vapors were collected in a receiver cooled with ice. After extraction with ether and distillation, the product was obtained as a colorless liquid boiling from 80°-84°C at 9 mm according to US Patent 2,590,079.The ether solution may be dried and saturated with hydrogen chloride and the precipitated hydrochloride recrystallized from a mixture of 50 parts alcohol and 100 parts of acetone.The pure hydrochloride is thus obtained as a white crystalline substance having a MP of 195°-196°C, according to US Patent 2,408,345.

Brand name

Ionamin (Fisons);Adipex nouveau;Adipex-p;Aneroxina;Bellapront;Dapex;Ex-adipos;Fastin;Inonamin;Ionakraft;Ionamine;Levum;Minobese forte;Mirapront;Netto-longcaps;Obestin 30;Oby-trim;Ona-mast;Panbesy;Panshape;Parmine;Phentermyl;Pronidin;Raucherstop 5 ht;Reducyl;Regulin;Span r/d;Teramine.

Therapeutic Function

Antiobesity

World Health Organization (WHO)

Phentermine, a sympathomimetic amine, was introduced in 1959 for use as an anorexic agent. It retains a place in the treatment of obesity. However,since it has been subject to abuse and because dependence can occur, phentermine is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)

Synthesis Reference(s)

Journal of the American Chemical Society, 70, p. 4048, 1948 DOI: 10.1021/ja01192a023

General Description

Oily liquid. Insoluble in water.

Air & Water Reactions

Insoluble in water.

Reactivity Profile

PHENTERMINE neutralizes acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. May generate hydrogen, a flammable gas, in combination with strong reducing agents such as hydrides.

Safety Profile

Poison by ingestion, intravenous, and intraperitoneal routes. Human systemic effects by ingestion: sympathomimetic. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx

Check Digit Verification of cas no

The CAS Registry Mumber 122-09-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,2 and 2 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 122-09:
(5*1)+(4*2)+(3*2)+(2*0)+(1*9)=28
28 % 10 = 8
So 122-09-8 is a valid CAS Registry Number.
InChI:InChI=1/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

122-09-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name phentermine

1.2 Other means of identification

Product number -
Other names Duromine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:122-09-8 SDS

122-09-8Related news

Case ReportParadoxical topiramate-induced hyperphagia successfully treated with PHENTERMINE (cas 122-09-8) in a woman with migraine09/24/2019

We report a 49-year-old female migraineur who experienced paradoxical hyperphagia and concurrent intrusive food thoughts leading to rapid weight gain and a substantial increase in waist circumference. A significant reduction in migraine frequency was also observed during topiramate treatment, a ...detailed

Clustering of PHENTERMINE (cas 122-09-8) HCL Drug from Online Patient Medication Reviews09/10/2019

In this paper, a study to reveal hidden knowledge in the online patient medication reviews for phentermine HCL is presented. Phentermine HCL is used most frequently in the treatment of obesity. Obesity is a complex health disorder that affects huge amount of people. In recent years, the number o...detailed

Clinical ScienceEffects of liraglutide plus PHENTERMINE (cas 122-09-8) in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial09/08/2019

BackgroundThis pilot study evaluated whether adding phentermine to liraglutide would induce further weight loss in participants who had previously lost weight with liraglutide alone.detailed

Lorcaserin vs. PHENTERMINE (cas 122-09-8) among non-surgical and surgical obese patients: Anthropometric, glycemic, lipid, safety and cost outcomes09/05/2019

BackgroundTo evaluate effectiveness, safety, and costs of Lorcaserin vs. phentermine among obese non–surgical and surgical patients (post bariatric surgery).detailed

122-09-8Relevant articles and documents

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Nguyen, Thuy,Gamage, Thomas F.,Decker, Ann M.,Finlay, David B.,Langston, Tiffany L.,Barrus, Daniel,Glass, Michelle,Harris, Danni L.,Zhang, Yanan

, (2021)

Allosteric modulation offers an alternate approach to target the cannabinoid type-1 receptor (CB1) for therapeutic benefits. Examination of the two widely studied prototypic CB1 negative allosteric modulators (NAMs) Org27569 and PSNCBAM-1 revealed structural resemblance and similar structure–activity relationships (SARs). In silico docking and dynamics simulation studies using the crystal structure of CB1 co-bound with CP55,940 and Org27569 suggested that Org27569 and PSNCBAM-1 occupied the same binding pocket and several common interactions were present in both series with the CB1 receptor. A new scaffold was therefore designed by merging the key structural features from the two series and the hybrids retained these binding features in the in silico docking studies. In addition, one such hybrid displayed similar functions to Org27569 in dynamic simulations by preserving a key R2143.50-D3386.30 salt bridge and maintaining an antagonist-like Helix3-Helix6 interhelical distance. Based on these results, a series of hybrids were synthesized and assessed in calcium mobilization, [35S]GTPγS binding and cAMP assays. Several compounds displayed comparable potencies to Org27569 and PSNCBAM-1 in these assays. This work offers new insight of the SAR requirement at the allosteric site of the CB1 receptor and provides a new scaffold that can be optimized for the development of future CB1 allosteric modulators.

Catalytic Intermolecular C(sp3)-H Amination: Selective Functionalization of Tertiary C-H Bonds vs Activated Benzylic C-H Bonds

Brunard, Erwan,Boquet, Vincent,Van Elslande, Elsa,Saget, Tanguy,Dauban, Philippe

supporting information, p. 6407 - 6412 (2021/05/29)

A catalytic intermolecular amination of nonactivated tertiary C(sp3)-H bonds (BDE of 96 kcal·mol-1) is reported for substrates displaying an activated benzylic site (BDE of 85 kcal·mol-1). The tertiary C(sp3)-H bond is selectively functionalized to afford α,α,α-Trisubstituted amides in high yields. This unusual site-selectivity results from the synergistic combination of Rh2(S-Tfpttl)4, a rhodium(II) complex with a well-defined catalytic pocket, with tert-butylphenol sulfamate (TBPhsNH2), which leads to a discriminating rhodium-bound nitrene species under mild oxidative conditions. This catalytic system is very robust, and the reaction was performed on a 50 mmol scale with only 0.01 mol % of catalyst. The TBPhs group can be removed under mild conditions to afford the corresponding NH-free amines.

ONE STEP PROCESS FOR THE PREPARATION OF PHENYL ETHYL AMINE DERIVATIVES

-

Page/Page column 6-7, (2021/06/11)

The present invention relates to a novel process for the preparation of phenyl ethyl amine derivatives by reacting a phenyl ethyl hydroxy compound with hydrogen cyanide followed by in situ hydrolysis.